Clinical trials: Alzheimer's Disease Dementia
Alzheimer, Alzheimer Dementia (AD)
Restoring Cervical Lymphatic Drainage in Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with the accumulation of abnormal proteins, including amyloid-beta and tau, in the brain.
- Trial name
- LymphDAD (NCT07854327)
- Testing
- Cervical lymphovenous anastomosis (LVA)
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- University of Siena
Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE
The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD).
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
- Trial name
- NCT07667478
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Chi-Ying (Roy) Lin
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's Disease Neuroimaging Initiative 4
The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- ADNI4 (NCT05617014)
- Testing
- Neuraceq, Amyvid, Tauvid
- Where
- 65 sites in United States, Canada
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Dementia
Improving PCP Advance Care Planning for People With ADRD
This study will test the Dementia Advance Care Planning (AD ACP) Toolkit intervention to usual care in facilitating goals of care (GOC) discussions between People Living with Dementia (PLwD) and primary care team members over an…
- Conditions
- Alzheimer Disease, Dementia, Alzheimer's Disease (Incl Subtypes), Aging
- Trial name
- AD-ACP (NCT06565169)
- Testing
- Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training, Care as Usual
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Pittsburgh
Agitation Associated With Alzheimer's Disease Dementia
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.
- Trial name
- NCT06803823
- Testing
- ONO-2020
- Where
- 39 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Mental Health (Depression), Mental Health and General Well-being
Thrive at Home: A Virtual Reality Social Intervention for Older Adults
The goal of this clinical trial is to evaluate whether a virtual reality (VR) based social platform can improve mental health and social connection for older adults who receive in-home care.
- Conditions
- Mental Health (Depression), Mental Health and General Well-being, Loneliness, Well Being
- Trial name
- Thrive at Home (NCT07835568)
- Testing
- Full Virtual Reality Social Intervention, Abbreviated Virtual Reality Social Intervention
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of California, Santa Barbara
Alzheimer Disease, Dementia
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT07839286
- Testing
- Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Callahan-Young LLC DBA Jigsawdio
Alzheimer Disease
A Study of LY3439539 in Participants With Alzheimer's Disease
The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.
- Trial name
- NCT07598370
- Testing
- LY3439539
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Transcranial Alternating Current Stimulation, Alzheimer Disease (AD)
Transcranial Alternating Current Stimulation (tACS) Combined With Cognitive Training in Alzheimer's Disease
The aim of the study is to evaluate the clinical and biological efficacy, as well as predictors of efficacy, of a home-based intervention combining transcranial alternating current stimulation (tACS) with individualized…
- Conditions
- Transcranial Alternating Current Stimulation, Alzheimer Disease (AD), Alzheimer Dementia (AD), Cognitive Rehabilitation
- Trial name
- AD_tACSrehab (NCT07839650)
- Testing
- Transcranial Alternating Current Stimulation, Individualized Computerized Memory Training
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Dementia, Mild Cognitive Impairment (MCI)
Combating Alzheimer's Through Sleep and Exercise
The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and…
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Cognitively Unimpaired, Alzheimer's Dementia (AD)
- Trial name
- CASE (NCT04855630)
- Testing
- Elemind Neuromodulation Headband, Exercise Routine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Miami
Alzheimer Dementia (AD)
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Trial name
- NCT07651319
- Testing
- IL-2 (Aldesleukin), Semaglutide Plus IL-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Alzheimer Disease, Dementia
Neurostimulation for Cognitive Enhancement in Alzheimer's Disease
The prevalence of Alzheimer's Disease (AD) is rising, but existing medications provide only modest control of cognitive decline and associated symptoms, and novel therapies are urgently needed.
- Trial name
- NICE-AD (NCT04404153)
- Testing
- tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Albert Einstein College of Medicine
Alzheimer Disease, Dementia
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05508789
- Testing
- Donanemab
- Where
- 141 sites in Argentina, Australia and 6 more
- Volunteers
- 1,500 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Predicting Pre-dementia
The goal of this observational study is to learn how well a multimodal "Progression and Risk" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Trial name
- NCT07516119
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prevention Research Consortium Corp.
Alzheimer's Disease
Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor
This study is designed to evaluate the efficacy on improving cognitive performance as well as the safety, tolerability, and pharmacokinetics (PK) of NBI-1117567 administered once daily (QD) in adults with mild to moderate AD who…
- Trial name
- NCT07832383
- Testing
- NBI-1117567
- Volunteers
- 135 people
- Sponsor
- Neurocrine Biosciences
Neurodegenerative Disease, Dementia
Cognition and Affective Research in China
This is a prospective cohort study of patients with cognitive impairment mood disorders and behavioral disorders. Comprehensive baseline and longitudinal follow-up assessments include clinical and epidemiological data, cognitive…
- Conditions
- Neurodegenerative Disease, Dementia, Alzheimer's Disease, Parkinson's Disease
- Trial name
- CARE (NCT07833267)
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease
Efficacy and Safety of Photobiomodulation Therapy in Patients With Mild Cognitive Impairment and Mild Alzheimer's Disease
The goal of this clinical trial is to learn if photobiomodulation therapy (PBMT) can help treat mild cognitive impairment and mild Alzheimer's disease in adults aged 50 to 85 years. It will also learn about the safety of PBMT.
- Conditions
- Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Dementia
- Trial name
- PBMT in MCI (NCT07835399)
- Testing
- Photobiomodulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jun Xu
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome